Daniel van den Bergh - Profile and Investment Details

Investor Profile

Daniel van den Bergh is a Corporate Venture Capital, Venture Capital based in United States with a diverse investment portfolio that includes companies such as iRhythm Technologies, Arcxis Biotechnologies, Kit Check, IntelyCare, NOCD, Astute Medical, Hemosphere, NuPathe, Proteus Digital Health, TriVascular, Nordic, Xanitos, Ingenious Med, Freenome, CytoPherx, CHF Solutions, Collective Medical Technologies, CareGuardian, Everytable, NextWeb, Valeritas, Big Health, Zonare Medical Systems, Vesta Healthcare, Arbor Surgical Technologies, MetricStream, Prognos, Movable, GluMetrics, Vidyo, Chrono Therapeutics, Accumetrics, Oxford Immunotec, Genome Medical, Bacchus Vascular, Omada Health, Torax Medical, Agile Therapeutics, Ordr, QuantiaMD, Kate Farms, Adiana, ValenTx, Nuvolo, HealthJoy, DexCare, Putney Vet, Sotera Wireless, Radianse, Evidation Health, Transcend Medical, Calypso Medical, Osso VR, Health Catalyst, Ginger, Validic, NextHealth Technologies, NeoGuide Systems, Vapotherm, Protenus, BDNA, AtheroMed, Predictive Biosciences, Baxano. Over time, Daniel van den Bergh has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Daniel van den Bergh is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Asset Management, Genetics, Wellness, Women Founded, Medical Testing, Enterprise Software, Women Led, Life Science, Information Services, Biotech, Analytics, Medical Device, Data Centers, Software, Healthcare, Biotechnology, Business Information Systems, Virtual Reality, Genomics, Health and Hospital Services, Nutrition, Drug Delivery, Food and Beverage, Health IT, Facility Management, Health Diagnostics, Digital Health, Medical, Big Data, Therapeutics, mHealth, Personal Health may find it worthwhile to explore potential connections with Daniel van den Bergh, as their portfolio suggests a familiarity and interest in this area.

Understanding Daniel van den Bergh’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.